14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
PACS vs BTSG: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, PACS Group, Inc. (PACS) is the stronger overall head-to-head candidate over BrightSpring Health Services, Inc. (BTSG) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). PACS carries a Unified Composite Score of 46.8/100 (HOLD) at $43.67 (15.3x Forward P/E, 7.4% operating margin), whereas BTSG carries 42.6/100 (HOLD) at $62.84 (25.9x Forward P/E, 3.5% operating margin).
Competes within the Health Information Services value chain with $12.7B market capitalization and 3.5% operating margin.
OpEx & R&D Reinvestment9.0% of Rev ($939M)
90D Engineering Disclosures0 Published
Investor FAQ PACS vs BTSG Key Questions & Quantitative Answers
As of Nov 20, 2026, PACS Group, Inc. (PACS) is the stronger overall head-to-head candidate over BrightSpring Health Services, Inc. (BTSG) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). PACS carries a Unified Composite Score of 46.8/100 (HOLD) at $43.67 (15.3x Forward P/E, 7.4% operating margin), whereas BTSG carries 42.6/100 (HOLD) at $62.84 (25.9x Forward P/E, 3.5% operating margin). Technically, PACS sits in a Neutral phase (RSI 39.2, CONSOLIDATION options structure) and BTSG sits in a Neutral phase (RSI 42.1, CONSOLIDATION options structure).
BTSG leads the Growth & Scale pillar: PACS posts +11.5% YoY revenue growth and +15.6% YoY earnings growth on $5.71B TTM revenue (17.8% gross margin, 7.4% operating margin), compared with BTSG at +26.4% YoY revenue growth and +82.0% YoY earnings growth on $10.4B TTM revenue (12.5% gross margin, 3.5% operating margin). Across the 4-period historical trajectory (FY2022 to FY2025), PACS cumulative revenue shifted +120.4% while BTSG shifted +67.2%. In operating R&D and SG&A reinvestment, PACS deploys 10.4% of Rev ($593M) (0 90-day corporate R&D disclosures) versus 9.0% of Rev ($939M) (0 disclosures) for BTSG.
PACS screens cheaper on headline valuation multiples. PACS trades at 15.3x Forward P/E, 26.2x Trailing P/E, 1.22x PEG, and 1.8x EV/Revenue (0.1% FCF margin), whereas BTSG trades at 25.9x Forward P/E, 45.4x Trailing P/E, N/M PEG, and 1.3x EV/Revenue (3.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PACS (26.5% ROE) versus BTSG (15.5% ROE) capital efficiency.
In options market volatility and institutional positioning, PACS carries 46.1% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.52x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.78β · 51% Vol realized risk). By comparison, BTSG carries 152.7% implied volatility (100th %ile, Extreme (>80th %ile)), a 1.69x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.94β · 59% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.